This Request for Information (RFI) seeks to identify organizations with AI capabilities for discovering broad-spectrum small-molecule therapeutics targeting filoviruses like Ebola and Marburg. The effort is expected to span AI-enabled discovery through preclinical in vivo testing in small animal models, with a preference for direct-acting antivirals. Responses must be submitted by email to rrpv@ati.org no later than 1pm EDT on June 17th, 2026. No budget amounts are specified in this RFI, which is for market research and acquisition planning only. The location for performance of services is not specified.

This Request for Information (RFI) seeks to identify organizations with AI capabilities for discovering broad-spectrum small-molecule therapeutics targeting filoviruses like Ebola and Marburg. The effort is expected to span AI-enabled discovery through preclinical in vivo testing in small animal models, with a preference for direct-acting antivirals showing activity across EBOV, SUDV, and MARV. Responses must be submitted by email to rrpv@ati.org no later than 1pm EDT on June 17th, 2026. No budget amounts are specified in this RFI, and the location for performance of services is not mentioned. This is a market research effort to inform future acquisition planning and does not constitute a solicitation for proposals.